"I am also aggressively working to greatly expand our relationships with pharmaceutical companies around the world. I believe that 2013 will be a breakthrough year for increased exposure of Sucanon into new markets. Our product is the only Type II Diabetes drug with no side effects and high efficacy. This incredible combination of attributes is the key strength of our company."
"In conclusion, I would like to say that we have been working very hard to increase our market penetration in turbulent corporate times. I believe we are now well positioned to move forward as a company in a more aggressive way. I look forward to 2013 and beyond!"
About Sucanon ®
Sucanon ® is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers". Pre-clinical and clinical studies show that Sucanon ® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon ® has been approved for prescription sale in China and Peru. Sucanon ® is also approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico, and is distributed there under an exclusive agreement with Merck S.A. de C.V.For further information regarding Sucanon ®, please visit the Fero Industries Inc. website at www.feroindustries.com. About Fero Industries Inc. Fero Industries, Inc. (OTC: FROI) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon ®, an oral treatment for Type-II diabetes. Sucanon ® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. Fero's strategy is to increase awareness, acceptance, and distribution of Sucanon ® globally. For investor relations contact: Michael Irving Paramount Advisors, LLC(407) 878-5462